Intensified antibiotic treatment of tuberculosis meningitis

Fiona V. Cresswell, Lindsey Te Brake, Rachel Atherton, Rovina Ruslami, Kelly Elise Dooley, Rob Aarnoutse, Reinout Van Crevel

Research output: Contribution to journalReview article

Abstract

Introduction: Meningitis is the most severe manifestation of tuberculosis, resulting in death or disability in over 50% of those affected, with even higher morbidity and mortality among patients with HIV or drug resistance. Antimicrobial treatment of Tuberculous meningitis (TBM) is similar to treatment of pulmonary tuberculosis, although some drugs show poor central nervous system penetration. Therefore, intensification of antibiotic treatment may improve TBM treatment outcomes. Areas covered: In this review, we address three main areas: available data for old and new anti-tuberculous agents; intensified treatment in specific patient groups like HIV co-infection, drug-resistance, and children; and optimal research strategies. Expert commentary: There is good evidence from preclinical, clinical, and modeling studies to support the use of high-dose rifampicin in TBM, likely to be at least 30 mg/kg. Higher dose isoniazid could be beneficial, especially in rapid acetylators. The role of other first and second line drugs is unclear, but observational data suggest that linezolid, which has good brain penetration, may be beneficial. We advocate the use of molecular pharmacological approaches, physiologically based pharmacokinetic modeling and pharmacokinetic-pharmacodynamic studies to define optimal regimens to be tested in clinical trials. Exciting data from recent studies hold promise for improved regimens and better clinical outcomes in future.

Original languageEnglish (US)
Pages (from-to)267-288
Number of pages22
JournalExpert Review of Clinical Pharmacology
Volume12
Issue number3
DOIs
StatePublished - Mar 4 2019

Fingerprint

Meningeal Tuberculosis
Anti-Bacterial Agents
Linezolid
Drug Resistance
Pharmacokinetics
Isoniazid
Therapeutics
Rifampin
Coinfection
Meningitis
Pulmonary Tuberculosis
Pharmaceutical Preparations
HIV Infections
Tuberculosis
Central Nervous System
Clinical Trials
HIV
Pharmacology
Morbidity
Mortality

Keywords

  • antituberculous therapy
  • intensified
  • TB meningitis
  • Tuberculous meningitis

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)

Cite this

Cresswell, F. V., Te Brake, L., Atherton, R., Ruslami, R., Dooley, K. E., Aarnoutse, R., & Van Crevel, R. (2019). Intensified antibiotic treatment of tuberculosis meningitis. Expert Review of Clinical Pharmacology, 12(3), 267-288. https://doi.org/10.1080/17512433.2019.1552831

Intensified antibiotic treatment of tuberculosis meningitis. / Cresswell, Fiona V.; Te Brake, Lindsey; Atherton, Rachel; Ruslami, Rovina; Dooley, Kelly Elise; Aarnoutse, Rob; Van Crevel, Reinout.

In: Expert Review of Clinical Pharmacology, Vol. 12, No. 3, 04.03.2019, p. 267-288.

Research output: Contribution to journalReview article

Cresswell, FV, Te Brake, L, Atherton, R, Ruslami, R, Dooley, KE, Aarnoutse, R & Van Crevel, R 2019, 'Intensified antibiotic treatment of tuberculosis meningitis', Expert Review of Clinical Pharmacology, vol. 12, no. 3, pp. 267-288. https://doi.org/10.1080/17512433.2019.1552831
Cresswell, Fiona V. ; Te Brake, Lindsey ; Atherton, Rachel ; Ruslami, Rovina ; Dooley, Kelly Elise ; Aarnoutse, Rob ; Van Crevel, Reinout. / Intensified antibiotic treatment of tuberculosis meningitis. In: Expert Review of Clinical Pharmacology. 2019 ; Vol. 12, No. 3. pp. 267-288.
@article{46c4c7509edd4d4b82001aa60adecc9c,
title = "Intensified antibiotic treatment of tuberculosis meningitis",
abstract = "Introduction: Meningitis is the most severe manifestation of tuberculosis, resulting in death or disability in over 50{\%} of those affected, with even higher morbidity and mortality among patients with HIV or drug resistance. Antimicrobial treatment of Tuberculous meningitis (TBM) is similar to treatment of pulmonary tuberculosis, although some drugs show poor central nervous system penetration. Therefore, intensification of antibiotic treatment may improve TBM treatment outcomes. Areas covered: In this review, we address three main areas: available data for old and new anti-tuberculous agents; intensified treatment in specific patient groups like HIV co-infection, drug-resistance, and children; and optimal research strategies. Expert commentary: There is good evidence from preclinical, clinical, and modeling studies to support the use of high-dose rifampicin in TBM, likely to be at least 30 mg/kg. Higher dose isoniazid could be beneficial, especially in rapid acetylators. The role of other first and second line drugs is unclear, but observational data suggest that linezolid, which has good brain penetration, may be beneficial. We advocate the use of molecular pharmacological approaches, physiologically based pharmacokinetic modeling and pharmacokinetic-pharmacodynamic studies to define optimal regimens to be tested in clinical trials. Exciting data from recent studies hold promise for improved regimens and better clinical outcomes in future.",
keywords = "antituberculous therapy, intensified, TB meningitis, Tuberculous meningitis",
author = "Cresswell, {Fiona V.} and {Te Brake}, Lindsey and Rachel Atherton and Rovina Ruslami and Dooley, {Kelly Elise} and Rob Aarnoutse and {Van Crevel}, Reinout",
year = "2019",
month = "3",
day = "4",
doi = "10.1080/17512433.2019.1552831",
language = "English (US)",
volume = "12",
pages = "267--288",
journal = "Expert Review of Clinical Pharmacology",
issn = "1751-2433",
publisher = "Expert Reviews Ltd.",
number = "3",

}

TY - JOUR

T1 - Intensified antibiotic treatment of tuberculosis meningitis

AU - Cresswell, Fiona V.

AU - Te Brake, Lindsey

AU - Atherton, Rachel

AU - Ruslami, Rovina

AU - Dooley, Kelly Elise

AU - Aarnoutse, Rob

AU - Van Crevel, Reinout

PY - 2019/3/4

Y1 - 2019/3/4

N2 - Introduction: Meningitis is the most severe manifestation of tuberculosis, resulting in death or disability in over 50% of those affected, with even higher morbidity and mortality among patients with HIV or drug resistance. Antimicrobial treatment of Tuberculous meningitis (TBM) is similar to treatment of pulmonary tuberculosis, although some drugs show poor central nervous system penetration. Therefore, intensification of antibiotic treatment may improve TBM treatment outcomes. Areas covered: In this review, we address three main areas: available data for old and new anti-tuberculous agents; intensified treatment in specific patient groups like HIV co-infection, drug-resistance, and children; and optimal research strategies. Expert commentary: There is good evidence from preclinical, clinical, and modeling studies to support the use of high-dose rifampicin in TBM, likely to be at least 30 mg/kg. Higher dose isoniazid could be beneficial, especially in rapid acetylators. The role of other first and second line drugs is unclear, but observational data suggest that linezolid, which has good brain penetration, may be beneficial. We advocate the use of molecular pharmacological approaches, physiologically based pharmacokinetic modeling and pharmacokinetic-pharmacodynamic studies to define optimal regimens to be tested in clinical trials. Exciting data from recent studies hold promise for improved regimens and better clinical outcomes in future.

AB - Introduction: Meningitis is the most severe manifestation of tuberculosis, resulting in death or disability in over 50% of those affected, with even higher morbidity and mortality among patients with HIV or drug resistance. Antimicrobial treatment of Tuberculous meningitis (TBM) is similar to treatment of pulmonary tuberculosis, although some drugs show poor central nervous system penetration. Therefore, intensification of antibiotic treatment may improve TBM treatment outcomes. Areas covered: In this review, we address three main areas: available data for old and new anti-tuberculous agents; intensified treatment in specific patient groups like HIV co-infection, drug-resistance, and children; and optimal research strategies. Expert commentary: There is good evidence from preclinical, clinical, and modeling studies to support the use of high-dose rifampicin in TBM, likely to be at least 30 mg/kg. Higher dose isoniazid could be beneficial, especially in rapid acetylators. The role of other first and second line drugs is unclear, but observational data suggest that linezolid, which has good brain penetration, may be beneficial. We advocate the use of molecular pharmacological approaches, physiologically based pharmacokinetic modeling and pharmacokinetic-pharmacodynamic studies to define optimal regimens to be tested in clinical trials. Exciting data from recent studies hold promise for improved regimens and better clinical outcomes in future.

KW - antituberculous therapy

KW - intensified

KW - TB meningitis

KW - Tuberculous meningitis

UR - http://www.scopus.com/inward/record.url?scp=85061806158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061806158&partnerID=8YFLogxK

U2 - 10.1080/17512433.2019.1552831

DO - 10.1080/17512433.2019.1552831

M3 - Review article

VL - 12

SP - 267

EP - 288

JO - Expert Review of Clinical Pharmacology

JF - Expert Review of Clinical Pharmacology

SN - 1751-2433

IS - 3

ER -